NASDAQ: ADMPAdamis Pharmaceuticals Corp Stock
$0.11-0.01 (-8.33%)
Updated Mar 17, 2023
ADMP Price
$0.11
Fair Value Price
$0.13
Market Cap
$16.50M
52 Week Low
$0.11
52 Week High
$0.68
P/E
-0.61x
P/B
-20.42x
P/S
5.33x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.76M
Earnings
-$26.48M
Gross Margin
-30.1%
Operating Margin
-557.61%
Profit Margin
-556.7%
Debt to Equity
-14.33
Operating Cash Flow
-$26M
Beta
0.76
Next Earnings
May 15, 2023
Ex-Dividend
N/A
Next Dividend
N/A
ADMP Overview
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ADMP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ADMP ($0.11) is undervalued by 14.07% relative to our estimate of its Fair Value price of $0.13 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ADMP ($0.11) is not significantly undervalued (14.07%) relative to our estimate of its Fair Value price of $0.13 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ADMP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ADMP due diligence checks available for Premium users.
Be the first to know about important ADMP news, forecast changes, insider trades & much more!
ADMP News
Valuation
ADMP fair value
Fair Value of ADMP stock based on Discounted Cash Flow (DCF)
Price
$0.11
Fair Value
$0.13
Undervalued by
14.07%
ADMP ($0.11) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ADMP ($0.11) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ADMP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ADMP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.61x
Industry
18.12x
Market
21.81x
ADMP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-20.42x
Industry
1.8x
ADMP's financial health
Profit margin
Revenue
$2.2M
Net Income
-$3.3M
Profit Margin
-154.7%
ADMP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ADMP's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$10.9M
Liabilities
$11.6M
Debt to equity
-14.33
ADMP's short-term liabilities ($11.40M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ADMP's short-term assets ($9.27M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ADMP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ADMP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.5M
Investing
$155.3k
Financing
$0.0
ADMP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ADMP vs Pharmaceutical Stocks
Adamis Pharmaceuticals Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.